Britain and America have signed a landmark trade agreement that will preserve no duties on UK medicine exports being sold in the American market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has pledged to raise funding on pharmaceuticals through the NHS. This move secures that import taxes on these vital goods will remain at nothing for a duration of three years.
This deal comes after recent threats to dramatically increase tariffs on branded pharmaceutical products, with increases floated as high as double the cost.
"This agreement with the United Kingdom strengthens the international landscape for cutting-edge drugs and brings much-needed equity to U.S.–U.K. medicine commerce," a statement noted.
Economic Impact
Drugs are one of the the United Kingdom's biggest export categories to the United States, which is by far the largest destination for large companies like GSK and AstraZeneca.
Export figures show that in the 12 months to the end of the third quarter, the UK exported drugs totaling £11.1bn to the US. This amount made up a significant portion of British export trade in that timeframe.
"This agreement safeguards work, boosts capital expenditure and sets the stage for the UK to become a worldwide center for biotech and pharma," a government official stated.
Detailed UK Commitments
The agreement includes several key changes from the British government:
- Revised Affordability Limit: The UK will increase the affordability limit at which it deems new therapies to be unaffordable by twenty-five percent.
- Increased NHS Spending: There is a aim to raise overall health service expenditure on treatments from 0.3% of Gross Domestic Product to 0.6 percent over the next decade.
- Refund Ceiling: The percentage pharmaceutical firms must pay back to the NHS to prevent overspending will be capped at fifteen percent. In the past, rebates were more than 20%.
Industry Background
The pact comes amid a long-running dispute between the pharmaceutical industry and the British authorities over spending levels and NHS adoption.
The disagreement were exacerbated by claims that American patients were charged significantly more for the identical medicines than people in the Britain and the EU.
Recently, several major pharmaceutical investments in the UK have been halted or scrapped, while substantial investments have been directed toward US facilities.
A senior figure publicly accepted that the NHS needed to increase expenditure on medicines, noting that its expenditure on drugs had declined as a percentage of its total funding over the past decade.
